BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (
), a developer and manufacturer of advanced medical systems that utilize heat therapy to treat cancer, announced today that a distinguished, international team of leading oncologists met in council while attending the May 2012 conference of the European Society for Radiotherapy and Oncology (ESTRO) in Barcelona, Spain. The team, known as the “Atzelberg Circle,” includes leading researchers from multiple internationally-renowned cancer research centers. The purpose of the meeting was to develop strategies to advance hyperthermia as standard cancer therapy in combination with radiation and chemotherapy.
To the great frustration of many leading oncologists, including the oncologists in the Atzelberg Circle, cancer death rates remain high. Better technologies and methods for the treatment of cancer are desperately needed. In strategizing its initiatives, the Atzelberg Circle reviewed impressive results from clinical trials showing that hyperthermia therapy can substantially improve patient outcomes when combined with radiation or chemotherapy for the treatment of glioblastoma (brain cancer), breast cancer, head and neck cancer, sarcomas, prostate cancer, peritoneal cancer and cervical cancer.
Members of the circle and their associates are currently conducting and planning clinical trials on the addition of hyperthermia therapy to standard treatments for pancreatic cancer, rectal cancer, anal cancer, bladder cancer, prostate cancer and peritoneal cancer.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.